Ipsen has announced Phase II corabotase data in glabellar lines, reporting sustained duration of effect and consistently high patient satisfaction.
The first clinical results involving 183 patients for its recombinant neuroinhibitor were shared during the 2026 Scale Symposium in Nashville, Tennessee, US, focusing on patients with moderate-to-severe glabellar lines.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
At week four of the trial, 66% of patients treated with corabotase (50ng) showed a statistically significant greater-than-or-equal-to two-grade improvement in line severity (composite response) compared to 0% for placebo, the primary endpoint.
In the comparator arm, 54.3% of patients who received Dysport experienced the same degree of improvement at week four.
At week 24, 60.8% of corabotase-treated patients maintained this clinically significant duration of effect versus placebo (0.2%) and Dysport (36.7%), as per investigator assessments.
Patient satisfaction scores reflected the treatment impact, with 82.8% of patients who received corabotase (50ng) reporting “very satisfied” or “satisfied” on the Subject Level of Satisfaction scale.
Ipsen executive vice-president and research and development head Christelle Huguet said: “We are pleased to share that these data demonstrated many firsts for the aesthetics industry.
“Patients are now experiencing a sustained duration of clinical effect, reinforced by superior patient treatment satisfaction. We are eagerly awaiting further data in upper facial lines later this year.”
Patient-reported data also indicated a rapid onset of action for corabotase (50ng) at 0.84 days and a positive safety profile, with adverse event frequency similar to Dysport and placebo.
The response in line severity was greater for corabotase than Dysport at week 36.
The 50ng dose of corabotase will undergo further evaluation in the Phase III LAURITE programme.
The ongoing Phase II LANTIC trial is expected to deliver proof-of-concept results for additional aesthetic uses in forehead and lateral canthal lines.
In December 2025, Ipsen’s fidrisertib failed to show meaningful benefit above placebo in a Phase II trial in patients with fibrodysplasia ossificans progressiva (FOP).
